Sign inJoin waitlistJoin the waitlist

Scott Plotkin

Program Co-Director, K12 Training Program in Nervous System Tumors · Mass General Brigham

Credentials: · · · ·

History

K12 Training Program in Nervous System Tumors · Mass General Brigham
Present
HCC Neuro-Oncology Program · Mass General Brigham
Present

Mass General Brigham
1999–2003
Tulane University School of Medicine
1994–1998

Research

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Cancer Cell · 2007 · 1,410 citations
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
Genetics in Medicine · 2021 · 627 citations
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Journal of Clinical Oncology · 2010 · 423 citations

Jaishri Blakeley
45 papers
Justin Jordan
43 papers · 5 as a fellow
AS
Anat Stemmer-Rachamimov
39 papers
Brigitte Widemann
27 papers
Tracy Batchelor
27 papers
Bruce Korf
20 papers
Michael Fisher
19 papers
Frederick Barker
16 papers
Nicole Ullrich
16 papers
AV
Ana-Maria Vranceanu
15 papers
EG
Elizabeth Gerstner
15 papers
PW
Patrick Wen
14 papers

Grants

Training Program in Nervous System Tumors
National Cancer Institute · K12
Contact PI · $5.6M · Massachusetts General Hospital
2001–2027
Neurofibromatosis and Schwannomatosis Genes Variant Curation Expert Panel (VCEP)
National Institute of Neurological Disorders and Stroke · U24
Contact PI · $861.5K · Massachusetts General Hospital
2024–2027
Phase II Trial of mTORC1/mTORC2 Inhibitor AZD2014 for Sporadic Meningioma
National Cancer Institute · R01
PI · $1.6M · Massachusetts General Hospital
2016–2022
Designing Clinical Trials for Cutaneous Neurofibromas, an Unmet Medical Need for Patients with Neurofibromatosis 1
National Cancer Institute · R13
Contact PI · $9.9K · Massachusetts General Hospital
2018–2020

Clinical trials

A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
Principal investigator · Completed
Massachusetts General Hospital
2024–2026
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Principal investigator · Recruiting · Phase 2
Massachusetts General Hospital
2023–2028
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Principal investigator · Recruiting · Phase 2
Scott R. Plotkin, MD, PhD
2020–2030
Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis
Principal investigator · Unknown · Phase 2
Massachusetts General Hospital
2020–2024